Press release
Culture Biosciences Selects Scispot.io as Its Preferred Digital Partner to Automate Biomanufacturing Workflows
Culture Biosciences implements Scispot to improve experiment reproducibility, SOP adherence, and compliance.
Culture Biosciences uses Scispot to digitize and automate its media preparation workflows end to end while maintaining the entire audit trail. It leverages Scispot's built-in template library and inventory automation module to standardize media preparation and automate inventory consumption and production, respectively. Connecting data from multiple sources with Scispot, Culture Biosciences aims to considerably reduce its experiment failure rate and improve the scientific output.
"Scispot is designed for mapping custom biomanufacturing workflows developed by Culture Biosciences. Using Scispot, Culture is increasing its experiment success rate and optimizing the usage of chemicals and recipes by automating its regular recipe thresholds and calculations," said Satya Singh, co-founder & CPO of Scispot.io.
"Scispot is just the platform we needed, and it has met many of our needs right out of the gate. Having Scispot in place to manage our inventory and media preparation documentation is going to help us scale our operations dramatically as we build out our lab and attract more customers," stated Satshabad Khalsa, Software Engineering Manager at Culture Biosciences.
ABOUT CULTURE BIOSCIENCES
Culture Biosciences is a biotechnology company based in South San Francisco, CA that is building the future of biomanufacturing. Culture's digital biomanufacturing platform enables companies to run, monitor, and analyze bioreactor experiments in the cloud. Culture is proud to count Section 32, Refactor Capital, and Verily among its investors and is a resident of the Verily Partner Space. To learn more, please visit www.culturebiosciences.com.
Scispot.io
22 Frederick St
Kitchener, Ontario, Canada, N2H6M6
Media Contact
Guru Singh
Founder & CEO @ Scispot.io
team@scispot.io
ABOUT SCISPOT.IO
Scispot.io is a Y Combinator-backed life science informatics company based in the Kitchener-Waterloo area. It has created the operating platform for fast-growing life science companies, including modern biomanufacturers, diagnostic labs, drug discovery companies, and contract research organizations (CROs). Scispot customers use the platform to design and automate their custom workflows at all stages of R&D and manufacturing, from planning, experiment execution to reporting collaboratively. To learn more, please visit www.scispot.io or book a product demo.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Culture Biosciences Selects Scispot.io as Its Preferred Digital Partner to Automate Biomanufacturing Workflows here
News-ID: 2428209 • Views: …
More Releases for Scispot
Laboratory Information Management System (LIMS) Market Size, Growth Analysis, Tr …
Laboratory Information Management System (LIMS) Market Size and Growth Analysis
The Laboratory Information Management System (LIMS) market is poised for significant growth between 2024 and 2032, driven by advancements in various industries like pharmaceuticals, biotech, chemical, agriculture, and more. LIMS solutions, available in multiple delivery models such as on-premise, cloud, SaaS, PaaS, and IaaS, provide robust data management and automation capabilities to streamline laboratory processes.
The market is segmented by industry, with…
Global Lab Automation Software market report, size, share, trends and forecast t …
According to Stratistics MRC, the Global Lab Automation Software Market is accounted for $13,760 million in 2022 and is expected to reach $22,201 million by 2028 growing at a CAGR of 8.3% during the forecast period.
Lab automation software is an effective tool that aids in standardising real-time analysis while removing specialised data handling, which is frequently prone to error.
Biotechnology as well as pharmaceutical companies are majorly investing in research and…
